Akeso, Inc.
9926
Rangering i aksjer
#1934
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery,... Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
Aksjekurs
$11.83
Markedsverdi
$10.89B
Endring (1 dag)
1.15%
Endring (1 år)
-23.08%
Land
CN
Handel Akeso, Inc. (9926)
Kategori
Healthcare
Inntekter for Akeso, Inc. (9926)
Inntekter i Jun 2026 TTM: $-142.22M
Ifølge Akeso, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-142.22M. I 2023 hadde selskapet et resultat på $274.42M, en økning sammenlignet med resultatet i 2022, som var $-206.18M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Akeso, Inc. fra 2018 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-142.22M | 107.17% |
| 2024 | $-68.65M | -125.02% |
| 2023 | $274.42M | -233.10% |
| 2022 | $-206.18M | 4.16% |
| 2021 | $-197.95M | -2.08% |
| 2020 | $-202.15M | 306.29% |
| 2019 | $-49.75M | 121.72% |
| 2018 | $-22.44M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -3,808.85% |
US
|
|
| $-3.09B | 2,070.51% |
US
|
|
| $-4.02B | 2,723.84% |
AU
|
|
| $1.95B | -1,471.53% |
NL
|
|
| - | - |
CH
|
